MARKET

BCRX

BCRX

BioCryst Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.910
-0.080
-4.02%
After Hours: 1.930 +0.02 +1.05% 17:59 03/27 EDT
OPEN
1.940
PREV CLOSE
1.990
HIGH
2.030
LOW
1.910
VOLUME
2.68M
TURNOVER
--
52 WEEK HIGH
9.26
52 WEEK LOW
1.380
MARKET CAP
294.51M
P/E (TTM)
-1.9424
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of BCRX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average BCRX stock price target is 7.13 with a high estimate of 13.00 and a low estimate of 4.000.

EPS

BCRX News

More
  • Edited Transcript of BCRX earnings conference call or presentation 5-Mar-20 1:30pm GMT
  • Thomson Reuters StreetEvents · 2d ago
  • BioCryst: Take Advantage Of Current Extreme Volatility To Buy At Bargain Prices
  • Seeking Alpha - Article · 03/17 18:33
  • DOW, REGN among premarket gainers
  • Seeking Alpha - Article · 03/17 13:22
  • Here's Why BioCryst Pharmaceuticals (NASDAQ:BCRX) Can Manage Its Debt Despite Losing Money
  • Simply Wall St. · 03/17 11:41

Industry

Biotechnology & Medical Research
-2.43%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About BCRX

BioCryst Pharmaceuticals, Inc. is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The Company's drug candidates include RAPIVAB, RAPIACTA, ALPIVAB, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, Galidesivir and Forodesine. Its product RAPIVAB contains peramivir. ALPIVAB is an intravenous neuraminidase inhibitor. Galidesivir is a broad-spectrum antiviral (BSAV) research program developed for the treatment of hemorrhagic fever viruses. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor in development by Mundipharma as a treatment for cancer.
More

Webull offers kinds of BioCryst Pharmaceuticals, Inc. stock information, including NASDAQ:BCRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCRX stock news, and many more online research tools to help you make informed decisions.